NAPLEX EXAM 2026–2027
225 QUESTIONS AND CORRECT ANSWERS
ALREADY GRADED A+ | 100% VERIFIED
Pharmacy Licensure & Clinical Practice
National Association of Boards of Pharmacy (NABP)
Key Domains: Pharmacotherapy | Pharmacokinetics | Medication Safety | Pharmacy Law &
Ethics | Patient Counseling | Sterile & Non-Sterile Compounding | Clinical Guidelines
The official, verified question count for the NAPLEX (North American Pharmacist Licensure
Examination) is exactly 225 multiple-choice questions.
,ANSWER FORMAT: Correct answers are displayed in bold cyan text, accompanied by
rationales explaining clinical reasoning and evidence-based practice. Answer distribution
(A, B, C, D) is intentionally randomized.
DOMAIN I: PHARMACOTHERAPY (Questions 1–33)
Question 1. First-line therapy for uncomplicated hypertension in a 55-year-old African
American patient without compelling indications is:
A. ACE inhibitor
B. Beta-blocker
C. ARB
D. Thiazide diuretic or calcium channel blocker
✓ Correct Answer: D
Rationale: Per JNC 8 and ACC/AHA guidelines, initial therapy for African American patients
without CKD should be a thiazide diuretic or CCB. ACE inhibitors and ARBs are less effective as
monotherapy in this population due to low-renin hypertension.
Question 2. A patient with HFrEF (LVEF 30%) should receive guideline-directed medical
therapy including:
A. ACE inhibitor/ARB/ARNI, beta-blocker, diuretic
B. ACE inhibitor/ARB/ARNI, beta-blocker, MRA, and SGLT2 inhibitor
C. Beta-blocker and CCB
D. Digoxin and hydralazine only
✓ Correct Answer: B
Rationale: GDMT for HFrEF includes four pillars: ACEi/ARB/ARNI (ARNI preferred), evidence-
based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), MRA (spironolactone or
eplerenone), and SGLT2 inhibitor (dapagliflozin or empagliflozin).
Question 3. The recommended duration of dual antiplatelet therapy (DAPT) after drug-
eluting stent placement for stable ischemic heart disease is:
A. 6 months minimum
B. 1 month
C. Indefinitely
D. 12 months
, ✓ Correct Answer: A
Rationale: For stable ischemic heart disease with DES, DAPT (aspirin + P2Y12 inhibitor) is
recommended for at least 6 months. For ACS, 12 months is recommended. Duration may be
shortened in high bleeding risk patients.
Question 4. First-line treatment for community-acquired pneumonia in a healthy
outpatient with no comorbidities is:
A. Respiratory fluoroquinolone
B. Amoxicillin or doxycycline or macrolide (in areas with low macrolide
resistance)
C. Vancomycin
D. Ceftriaxone plus azithromycin
✓ Correct Answer: B
Rationale: For healthy outpatients without comorbidities, IDSA/ATS guidelines recommend
amoxicillin, doxycycline, or macrolide (only if local pneumococcal resistance <25%). Respiratory
fluoroquinolones are reserved for patients with comorbidities.
Question 5. The target INR for a patient with a mechanical mitral valve is:
A. 2.0-3.0
B. 3.0-4.0
C. 1.5-2.0
D. 2.5-3.5
✓ Correct Answer: D
Rationale: Mechanical mitral valves require higher intensity anticoagulation (INR 2.5-3.5)
compared to mechanical aortic valves (INR 2.0-3.0) due to higher thrombosis risk in the mitral
position.
Question 6. First-line pharmacotherapy for major depressive disorder includes:
A. MAO inhibitors
B. Benzodiazepines
C. SSRIs, SNRIs, bupropion, or mirtazapine
D. Tricyclic antidepressants
✓ Correct Answer: C
Rationale: First-line agents for MDD include SSRIs (sertraline, escitalopram), SNRIs (venlafaxine,
duloxetine), bupropion, and mirtazapine based on efficacy, tolerability, and patient-specific
factors. TCAs and MAOIs are reserved for treatment-resistant cases.
Question 7. The preferred initial therapy for type 2 diabetes mellitus is:
, A. GLP-1 agonist
B. Metformin plus lifestyle modifications
C. Sulfonylurea
D. Insulin
✓ Correct Answer: B
Rationale: Metformin plus lifestyle modifications (diet, exercise, weight loss) is first-line for T2DM
per ADA guidelines, unless contraindicated. It's effective, safe, inexpensive, and has cardiovascular
benefits.
Question 8. Appropriate empiric therapy for hospital-acquired pneumonia with risk for
Pseudomonas and MRSA includes:
A. Amoxicillin alone
B. Antipseudomonal beta-lactam plus antipseudomonal fluoroquinolone or
aminoglycoside, plus vancomycin or linezolid
C. Ceftriaxone alone
D. Azithromycin monotherapy
✓ Correct Answer: B
Rationale: HAP with risk for Pseudomonas and MRSA requires broad-spectrum coverage:
antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, meropenem) PLUS second
antipseudomonal agent (fluoroquinolone or aminoglycoside) PLUS MRSA coverage (vancomycin or
linezolid).
Question 9. The target LDL-C for a patient with clinical ASCVD on maximally tolerated
statin therapy is:
A. <100 mg/dL
B. No specific target
C. <70 mg/dL
D. <130 mg/dL
✓ Correct Answer: C
Rationale: For very high-risk ASCVD patients, ACC/AHA guidelines recommend LDL-C <70 mg/dL.
If LDL remains ≥70 mg/dL on maximally tolerated statin, add ezetimibe, then consider PCSK9
inhibitor.
Question 10. First-line treatment for acute gout flare is:
A. NSAIDs, colchicine, or corticosteroids
B. Allopurinol
C. Febuxostat
D. Probenecid
225 QUESTIONS AND CORRECT ANSWERS
ALREADY GRADED A+ | 100% VERIFIED
Pharmacy Licensure & Clinical Practice
National Association of Boards of Pharmacy (NABP)
Key Domains: Pharmacotherapy | Pharmacokinetics | Medication Safety | Pharmacy Law &
Ethics | Patient Counseling | Sterile & Non-Sterile Compounding | Clinical Guidelines
The official, verified question count for the NAPLEX (North American Pharmacist Licensure
Examination) is exactly 225 multiple-choice questions.
,ANSWER FORMAT: Correct answers are displayed in bold cyan text, accompanied by
rationales explaining clinical reasoning and evidence-based practice. Answer distribution
(A, B, C, D) is intentionally randomized.
DOMAIN I: PHARMACOTHERAPY (Questions 1–33)
Question 1. First-line therapy for uncomplicated hypertension in a 55-year-old African
American patient without compelling indications is:
A. ACE inhibitor
B. Beta-blocker
C. ARB
D. Thiazide diuretic or calcium channel blocker
✓ Correct Answer: D
Rationale: Per JNC 8 and ACC/AHA guidelines, initial therapy for African American patients
without CKD should be a thiazide diuretic or CCB. ACE inhibitors and ARBs are less effective as
monotherapy in this population due to low-renin hypertension.
Question 2. A patient with HFrEF (LVEF 30%) should receive guideline-directed medical
therapy including:
A. ACE inhibitor/ARB/ARNI, beta-blocker, diuretic
B. ACE inhibitor/ARB/ARNI, beta-blocker, MRA, and SGLT2 inhibitor
C. Beta-blocker and CCB
D. Digoxin and hydralazine only
✓ Correct Answer: B
Rationale: GDMT for HFrEF includes four pillars: ACEi/ARB/ARNI (ARNI preferred), evidence-
based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), MRA (spironolactone or
eplerenone), and SGLT2 inhibitor (dapagliflozin or empagliflozin).
Question 3. The recommended duration of dual antiplatelet therapy (DAPT) after drug-
eluting stent placement for stable ischemic heart disease is:
A. 6 months minimum
B. 1 month
C. Indefinitely
D. 12 months
, ✓ Correct Answer: A
Rationale: For stable ischemic heart disease with DES, DAPT (aspirin + P2Y12 inhibitor) is
recommended for at least 6 months. For ACS, 12 months is recommended. Duration may be
shortened in high bleeding risk patients.
Question 4. First-line treatment for community-acquired pneumonia in a healthy
outpatient with no comorbidities is:
A. Respiratory fluoroquinolone
B. Amoxicillin or doxycycline or macrolide (in areas with low macrolide
resistance)
C. Vancomycin
D. Ceftriaxone plus azithromycin
✓ Correct Answer: B
Rationale: For healthy outpatients without comorbidities, IDSA/ATS guidelines recommend
amoxicillin, doxycycline, or macrolide (only if local pneumococcal resistance <25%). Respiratory
fluoroquinolones are reserved for patients with comorbidities.
Question 5. The target INR for a patient with a mechanical mitral valve is:
A. 2.0-3.0
B. 3.0-4.0
C. 1.5-2.0
D. 2.5-3.5
✓ Correct Answer: D
Rationale: Mechanical mitral valves require higher intensity anticoagulation (INR 2.5-3.5)
compared to mechanical aortic valves (INR 2.0-3.0) due to higher thrombosis risk in the mitral
position.
Question 6. First-line pharmacotherapy for major depressive disorder includes:
A. MAO inhibitors
B. Benzodiazepines
C. SSRIs, SNRIs, bupropion, or mirtazapine
D. Tricyclic antidepressants
✓ Correct Answer: C
Rationale: First-line agents for MDD include SSRIs (sertraline, escitalopram), SNRIs (venlafaxine,
duloxetine), bupropion, and mirtazapine based on efficacy, tolerability, and patient-specific
factors. TCAs and MAOIs are reserved for treatment-resistant cases.
Question 7. The preferred initial therapy for type 2 diabetes mellitus is:
, A. GLP-1 agonist
B. Metformin plus lifestyle modifications
C. Sulfonylurea
D. Insulin
✓ Correct Answer: B
Rationale: Metformin plus lifestyle modifications (diet, exercise, weight loss) is first-line for T2DM
per ADA guidelines, unless contraindicated. It's effective, safe, inexpensive, and has cardiovascular
benefits.
Question 8. Appropriate empiric therapy for hospital-acquired pneumonia with risk for
Pseudomonas and MRSA includes:
A. Amoxicillin alone
B. Antipseudomonal beta-lactam plus antipseudomonal fluoroquinolone or
aminoglycoside, plus vancomycin or linezolid
C. Ceftriaxone alone
D. Azithromycin monotherapy
✓ Correct Answer: B
Rationale: HAP with risk for Pseudomonas and MRSA requires broad-spectrum coverage:
antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, meropenem) PLUS second
antipseudomonal agent (fluoroquinolone or aminoglycoside) PLUS MRSA coverage (vancomycin or
linezolid).
Question 9. The target LDL-C for a patient with clinical ASCVD on maximally tolerated
statin therapy is:
A. <100 mg/dL
B. No specific target
C. <70 mg/dL
D. <130 mg/dL
✓ Correct Answer: C
Rationale: For very high-risk ASCVD patients, ACC/AHA guidelines recommend LDL-C <70 mg/dL.
If LDL remains ≥70 mg/dL on maximally tolerated statin, add ezetimibe, then consider PCSK9
inhibitor.
Question 10. First-line treatment for acute gout flare is:
A. NSAIDs, colchicine, or corticosteroids
B. Allopurinol
C. Febuxostat
D. Probenecid
